Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miloš D Miljković

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancer Journal (Sudbury, Mass.)|September 21, 2013
From the Euthanasia Society to physician orders for life-sustaining treatment: end-of-life care in the United StatesMiloš D Miljković, Barbara L Jones, Kenneth Miller
Nature Reviews Bioengineering|June 26, 2023
Transforming bioengineering with unbiased teams and toolsChristopher M Jewell, Miloš D Miljković, Robert S Oakes
Journal of Palliative Medicine|April 1, 2015
"Allow Natural Death" versus "Do Not Resuscitate": What Do Patients with Advanced Cancer Choose?Miloš D Miljković, Dennis Emuron, Lori Rhodes, et al.
Cancer Investigation|January 9, 2016
Patterns of Radiation-Associated Lymphopenia in Children with CancerMiloš D Miljković, Stuart A Grossman, Xiaobu Ye, et al.
Science Translational Medicine|October 30, 2024
Engineering CAR-T therapies for autoimmune disease and beyondEmily P English, Rachel N Swingler, Simran Patwa, et al.
Histochemistry and Cell Biology|May 26, 2011
Role of CCL19/21 and its possible signaling through CXCR3 in development of metallophilic macrophages in the mouse thymusNovica M Milićević, Miloš D Miljković, Zivana Milićević, et al.
Annals of Clinical and Translational Neurology|August 26, 2025
Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia GravisNizar Chahin, Gregory Sahagian, Marc H Feinberg, et al.
The Lancet. Neurology|June 23, 2023
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Michael Benatar, Metin Kurtoglu, et al.
Nature Medicine|January 9, 2026
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trialRenee R Fedak, Rachel N Ruggerie, Yufei Shan, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer Journal (Sudbury, Mass.)|September 21, 2013
From the Euthanasia Society to physician orders for life-sustaining treatment: end-of-life care in the United StatesMiloš D Miljković, Barbara L Jones, Kenneth Miller
Nature Reviews Bioengineering|June 26, 2023
Transforming bioengineering with unbiased teams and toolsChristopher M Jewell, Miloš D Miljković, Robert S Oakes
Journal of Palliative Medicine|April 1, 2015
"Allow Natural Death" versus "Do Not Resuscitate": What Do Patients with Advanced Cancer Choose?Miloš D Miljković, Dennis Emuron, Lori Rhodes, et al.
Cancer Investigation|January 9, 2016
Patterns of Radiation-Associated Lymphopenia in Children with CancerMiloš D Miljković, Stuart A Grossman, Xiaobu Ye, et al.
Science Translational Medicine|October 30, 2024
Engineering CAR-T therapies for autoimmune disease and beyondEmily P English, Rachel N Swingler, Simran Patwa, et al.
Histochemistry and Cell Biology|May 26, 2011
Role of CCL19/21 and its possible signaling through CXCR3 in development of metallophilic macrophages in the mouse thymusNovica M Milićević, Miloš D Miljković, Zivana Milićević, et al.
Annals of Clinical and Translational Neurology|August 26, 2025
Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia GravisNizar Chahin, Gregory Sahagian, Marc H Feinberg, et al.
The Lancet. Neurology|June 23, 2023
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Michael Benatar, Metin Kurtoglu, et al.
Nature Medicine|January 9, 2026
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trialRenee R Fedak, Rachel N Ruggerie, Yufei Shan, et al.
Pageof 1